跳到正文
ECA GMP News·AI 评分75

EMA发布EU GMP附录15修订概念文件,拟强制适用于原料药

Revision of EU-GMP Annex 15: Increased Focus on Deviation Management

AI 导读

EMA网站发布EU GMP附录15修订概念文件,拟将附录15对原料药(API)的适用由可选改为强制,并纳入ICH Q9(R1)的质量风险管理更新。概念文件提及沙坦类产品中的N-亚硝胺问题,指出开发阶段工艺与产品知识不足、对质量问题的调查不充分是因素之一。公开征求意见期为两个月,至2026年4月,最终草案版本预计2026年底可用。

正文 · 原文

A concept paper on the revision of Annex 15 has been published on the EMA's website. One of the main objectives of the revision is to make the application of Annex 15 mandatory for active substances (APIs). Until now, its application has been optional for active substance manufacturers. This change will affect both manufacturers of chemically synthesized and biologically derived active substances. In addition, the updates to Quality Risk Management introduced in ICH Q9 (R1) will be incorporated. In this context, the concept paper further emphasises the need for thorough investigations in cases where deviations from predefined acceptance criteria occur. This is intended to promote a deeper understanding of manufacturing processes among API manufacturers. The document explicitly refers to the presence of N-nitrosamines in sartan products. According to the concept paper, one contributing factor "was the lack of sufficient process and product knowledge during the development stage and GMP deficiencies by active substance manufacturers, including inadequate investigation of quality issues …". Why this matters to manufacturers of drug product and QPs? Strengthened oversight responsibilities: If Annex 15 becomes mandatory for APIs, drug product manufacturers and QPs will need to ensure that processes at API manufacturers meet the revised expectations. Supply chain implications: The changes will likely affect technical agreements, audit scopes and QP declarations for APIs. A two-month public consultation period is planned until April 2026. A final draft version is expected to be available by the end of 2026. The full concept paper is available on the EMA's website

来源:ECA GMP News · gmp-compliance.org